Table 2.
Univariate analysis by patient characteristic of seroconversion and seroprotection rates and mean fold increase (MFI) in geometric mean titre after prime and booster vaccine dose
| Characteristic | Variable | After prime vaccine dose | After booster vaccine dose | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seroconversion n/N (%) | P | Seroprotection n/N (%) | P | MFI titres mean(95% CI) | P | Seroconversion n/N (%) | P | Seroprotection n/N (%) | P | MFI titres mean (95% CI) | P | ||
| Total | – | 18/24 (75) | – | 21/24 (88) | – | 8·0 (4·9–13·1) | – | 17/24 (71) | – | 21/24 (88) | – | 8·0 (4·4–14·5) | – |
| Gender | Female | 7/11 (64) | 0·37 | 9/11 (82) | 0·58 | 11·3 (5·7–22·6) | 0·09 | 7/11 (64) | 0·66 | 9/11 (82) | 0·58 | 12·3 (5–29·9) | 0·14 |
| Male | 11/13 (85) | 12/13 (92) | 5·3 (2·5–11·3) | 10/13 (77) | 12/13 (92) | 4·8 (2·2–10·8) | |||||||
| Ethnicity | African | 15/18 (83) | 0·29 | 17/18 (94) | 0·11 | 8·8 (4·8–16·1) | 0·48 | 13/18 (72) | >0·99 | 16/18 (89) | 0·54 | 6·9 (3·6–13·1) | 0·33 |
| Caucasian | 3/5 (60) | 3/5 (60) | 7·5 (2·0–27·5) | 4/5 (80) | 4/5 (80) | 18·4 (2·4–143) | |||||||
| CDC clinical stage | N/A | 8/8 (100) | 0·07 | 8/8 (100) | 0·53 | 13·4 (7·4–24·5) | 0·15 | 8/8 (100) | 0·05 | 8/8 (100) | 0·53 | 12·9 (5·7–29·2) | 0·14 |
| B/C | 10/16 (63) | 13/16 (81) | 6·2 (3·1–12·2) | 9/16 (56) | 13/16 (81) | 6·3 (2·8–14·4) | |||||||
| HAART | No | 3/4 (75) | >0·99 | 4/4 (100) | >0·99 | 8·9 (5·3–14·9) | 0·37 | 1/4 (25) | 0·06 | 3/4 (75) | 0·44 | 10·6 (6·0–18·6) | 0·07 |
| Yes | 15/20 (75) | 17/20 (85) | 4·8 (0·4–53) | 16/20 (80) | 18/20 (90) | 2 (0·2–29·2) | |||||||
| HAART regimen | NNRTI-based | 5/6 (83) | 0·83 | 6/6 (100) | >0·99 | 8·2 (4·2–16·1) | 0·77 | 5/6 (83) | 0·83 | 6/6 (100) | >0·99 | 10·5 (5–22·2) | 0·77 |
| PI-based | 10/14 (71) | 11/14 (79) | 10·7 (3·6–31·8) | 11/14 (79) | 12/14 (86) | 10·7 (3·4–33·3) | |||||||
| HIV virological suppression | Yes | 13/17 (77) | >0·99 | 15/17 (88) | >0·99 | 9·2 (5·1–16·7) | 0·34 | 15/17 (88) | 0·009* | 17/17 (100) | 0·017* | 12·3 (6·5–23·4) | 0·02* |
| No | 5/7 (71) | 6/7 (86) | 5·7 (1·8–17·7) | 2/7 (29) | 4/7 (57) | 2·8 (0·9–9·2) | |||||||
| Vaccine dose | 0·25 ml | 12/15 (80) | 0·64 | 14/15 (93) | 0·53 | 7·1 (3·2–15·9) | 0·42 | 10/15 (67) | 0·67 | 13/15 (87) | >0·99 | 11·8 (3·6–38) | 0·63 |
| 0·5 ml | 6/9 (67) | 7/9 (78) | 8·6 (4·2–17·4) | 7/9 (78) | 8/9 (89) | 6·3 (3·0–13·3) | |||||||
P-values calculated using Fisher's exact test or the chi-squared test for seroconversion/seroprotection rates and Wilcoxon rank sum test for MFI in geometric mean titre.
*
Statistical significance with a P-value <0·05.